<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942759</url>
  </required_header>
  <id_info>
    <org_study_id>BC-PET-MR-01</org_study_id>
    <nct_id>NCT01942759</nct_id>
  </id_info>
  <brief_title>The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer</brief_title>
  <official_title>The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine findings of positron emission tomography and
      diffusion weighted magnetic resonance in primary lesion and axillary metastasis of breast
      cancer and compare of two imaging modality in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aimed that to correlate both primary lesion 18F-fluorodeoxyglucose (FDG) maximum
      standardized uptake value (SUVmax) and diffusion-weighted imaging (DWI) apparent diffusion
      coefficient (ADC) with clinicopathological prognostic factors and compare the prognostic
      value of these indexes in breast cancer in this study. The evaluated and compared parameters
      are SUVmax and ADC according to age, tumour size, lymph node metastasis, receptor status,
      histologic grade, modified Nottingham prognostic index.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the relationships between both SUVmax and ADC and clinicopathological prognostic factors</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Histologic grade</arm_group_label>
    <description>According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axillary metastasis</arm_group_label>
    <description>Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified Nottingham prognostic index</arm_group_label>
    <description>NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)
The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (&gt;5.4) prognostic groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oestrogen receptor status</arm_group_label>
    <description>Negative Positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone receptor status</arm_group_label>
    <description>Negative Positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER-2 neu status</arm_group_label>
    <description>Negative Positive</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Female patients with breast cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosis of breast cancer for which surgical intervention is planned

        Exclusion Criteria:

          -  patients received neoadjuvant chemotherapy

          -  before breast surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AYNUR OZEN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Bagcilar Training &amp; Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagcilar Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>June 8, 2014</last_update_submitted>
  <last_update_submitted_qc>June 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bagcilar Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Aynur Ozen</investigator_full_name>
    <investigator_title>Aynur Ozen</investigator_title>
  </responsible_party>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Diffusion Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

